To determine the structural basis for binding subtype selective agonists in the ␤-adrenergic receptor (␤AR), we examined the interaction of the mutant ␤ 2 AR and chimeric ␤ 1 /␤ 2 AR with a selective ␤ 2 AR agonist, TA-2005 (8-hydroxy-5
TA-2005 lost ␤ 2 AR subtype selectivity. When the second and seventh transmembrane (TM) region but not the TM1 region of the ␤ 2 AR were replaced with the corresponding regions of the ␤ 1 AR, the affinities of the chimeras for TA-2005 decreased compared with those of the wild type ␤ 2 AR. Furthermore, substitution of the TM7 region of the ␤ 1 AR with the corresponding region of the ␤ 2 AR significantly increased the affinities for TA-2005. The affinities for isoproterenol and compounds II and III were not affected in the chimeras. These data suggest that the TM7 region of the ␤ 2 AR plays an important role in ␤ 2 -selective agonist binding. To determine the specific amino acid which confers this high affinity binding of TA-2005 to the ␤ 2 AR, an alanine-scanning mutagenesis approach was employed. All amino acids that were different from those of the ␤ 1 AR were individually changed to alanine. One mutant receptor (Y308A-␤ 2 AR) out of 10 point-mutated ␤ 2 ARs showed a dramatically reduced affinity for TA-2005. These results indicate that Tyr308 is an essential amino acid for high affinity binding of the ␤ 2 -selective agonist TA-2005. ARs are members of the G protein-coupled receptor superfamily and are classified into three groups (i.e., ␣ 1 , ␣ 2 , and ␤) (Bylund et al., 1994; Hieble et al., 1995) . ␤ARs consist of three subtypes, ␤ 1 , ␤ 2 , and ␤ 3 . Endogenous agonists, norepinephrine, epinephrine, and the synthetic full agonist isoproterenol bind to the ␤ 2 AR and induced conformational changes to activate the G protein. Mutagenesis experiments have revealed that the binding sites of isoproterenol on the ␤ 2 AR seem to be located in the TM regions Dohlman et al., 1988) . It is assumed that aspartic acid at position 113 in the TM3 region of the ␤ 2 AR form an ionic bond with the amino group of isoproterenol (Strader et al., , 1989a . It is also assumed that the catechol hydroxyl groups of the agonist isoproterenol interact with the side chains of Ser204 and Ser207 in the TM5 region of the receptor (Strader et al., 1989b) . Although the TM regions are well conserved among the three ␤AR subtypes (70% for ␤ 1 versus ␤ 2 , 70% for ␤ 1 versus ␤ 3 , 63% for ␤ 2 versus ␤ 3 ), the ␤ 1 AR and the ␤ 2 AR show different affinities for the various synthetic agonists and antagonists including the endogenous agonist norepinephrine (Emorine et al., 1989; Frielle et al., 1987; Kobilka et al., 1987; Stiles and Lefkowitz, 1984) . Frielle et al. (1988) have constructed a series of chimeric ␤ 1 /␤ 2 ARs to analyze the binding domains of ␤ 1 -and ␤ 2 -selective ligands. The gradual replacement of the TM regions of the ␤ 2 AR with those of the ␤ 1 AR result in receptors that show a gradual loss of ␤ 2 AR selectivity and a gain in ␤ 1 AR selectivity. The ␤ 1 ARs with homologous replacement show a gradual loss of ␤ 1 AR selectivity and a gain in ␤ 2 AR selectivity. Frielle et al. (1988) have concluded that the TM4 region is a major determinant of the ␤ 1 and ␤ 2 AR selectivity of agonist norepinephrine and that the TM6 or TM7 regions play a major role in determining ␤ 2 AR selectivity for the ␤ 2 AR antagonist ICI 118551 or a ␤ 1 AR selectivity for ␤ 1 AR antagonist betaxolol. Another group has employed the approach to randomly exchange the TM regions of the ␤ARs and determine the binding characteristics of subtype selective antagonists in these chimeric receptors (Marullo et al., 1990) . They have shown that the TM region's contribution to the subtype selective binding of the ␤ 1 and ␤ 2 ARs differed between ligands. However, the random exchange of the TM regions may underestimate or overestimate the contribution of some TM regions to binding of a subtype selective ligand, because more than one TM region mutates at once and it is possible that some TM region are not involved in the subtype selective binding. Thus, determining which regions of the ␤AR confer the subtype selectivity, especially for agonists, has so far been only tentative.
TA-2005 is a non-catechol ␤ 2 AR agonist with a p-methoxyphenyl group on the amine side chain and a 8-hydroxyl group on the carbostyril aromatic ring (see Fig. 1 ). We have previously shown that, compared with other ␤ 1 and ␤ 2 ARs, TA-2005 has a high selectivity as well as a high affinity for the ␤ 2 AR in pharmacological and radioligand-binding studies using isolated guinea pig tissues (Kikkawa et al., 1991) . Based on in vivo studies, we have reported that TA-2005 has long lasting bronchodilating effects (Kikkawa et al., 1994) . Voss et al. (1992) have also reported that TA-2005 shows a high potency for the ␤ 2 AR and a long duration of action after removal of the drug using both guinea pig tracheal muscle relaxation and bovine trapezium muscle binding experiments.
In the present study we putatively assigned the binding sites of the ␤ 2 AR for carbostyril moiety of TA-2005 and determined the specific amino acid to be responsible for ␤ 2 -selective binding. We made several site-directed mutant ␤ 2 ARs and eight chimeric ␤ 1 /␤ 2 ARs, which were expressed in COS-7 cells, then analyzed the binding characteristics of TA-2005 and derivatives for these receptors, and compared these characteristics with those of isoproterenol. (Brea, CA) . The plasmid constructs pBC-␤ 1 and -␤ 2 encoding for the human ␤ 1 and ␤ 2 ARs were kindly provided by Dr. R. J. Lefkowitz (Duke University, Durham, NC). The mammalian expression vector pEF-BOS was a gift of Dr. S. Nagata (Osaka University, Osaka, Japan). (Ϫ)Isoproterenol, (Ϯ)propranolol, and DEAE-dextran were purchased from Sigma Chemical (St. Louis, MO). DMEM and gentamicin were from GIBCO/BRL (Grand Island, NY). Fetal bovine serum was obtained from JRH Biosciences (Lenexa, KS). Taq or Pfu DNA polymerases were from Takara (Siga, Japan) or Stratagene (La Jolla, CA), respectively. GTP was from Seikagaku (Tokyo, Japan). TA-2005 (8-hydroxy-5 DNA constructions, cell transfection, and culture. The epitope sequence (YPYDVPDYA) recognized by monoclonal antibody 12CA5 (Wilson et al., 1984) was inserted at the amino terminus of human ␤ 1 and ␤ 2 ARs to evaluate the expression of the receptors (Barak et al., 1994; Sato et al., 1996; Von Zastrow and Kobilka, 1992) . The epitope did not change the binding characteristics of ␤ 1 and ␤ 2 ARs to the ligands (data not shown). Chimeric receptors and sitedirected mutants of the ␤ 1 and ␤ 2 ARs were constructed by the polymerase chain reaction method (Higuchi, 1989) (Sanger et al., 1977) . Chimeric and mutated cDNAs were inserted into the EcoRI and BamHI or EcoRI and SalI sites of the mammalian expression vector pCMV5. The alanine-scanning point mutants of the ␤ 2 AR were made by the Quick change method according to manufacture's instructions (Stratagene, La Jolla, CA). The two oligonucleotides (33-36 base pairs) and the BglII/EcoRV fragment of the ␤ 2 AR in pSL1190 (Pharmacia LKB, Uppsala, Sweden) were used as primers or as a template, respectively. After the sequences were confirmed by the dideoxy chain termination method, the rest of the coding regions were ligated to make point-mutated full-length ␤ 2 ARs. The resulting constructs were inserted into the XbaI site of pEF-BOS (Mizushima and Nagata, 1990) . For the binding studies, these constructs were transfected into COS-7 cells by the DEAE-dextran method (Cullen, 1987) . Before the day of transfection, the COS-7 cells were seeded at 1.5 ϫ 10 6 cells per 100-mm dish. The concentration of the chimeric or mutated ␤AR cDNAs were 5 g per 100-mm dish. All cells were maintained in DMEM containing 10% fetal bovine serum and gentamicin (10 g/ml). Two to three days after the transfection, the cells were harvested for preparation of the crude membrane fraction. For the cAMP accumulation assay, the expression constructs of WT-, S204A-, and S207A-␤ 2 ARs were transfected into the JEG-3 cells as described above, except that the concentration of DEAE-dextran was reduced to 250 g/ml and the JEG-3 cells were seeded at 1.5-2.0 ϫ 10 6 cells/100-mm dish. The JEG-3 cells were maintained in DMEM containing 10% fetal bovine serum and gentamicin (10 g/ml).
Experimental Procedures

Materials
Radioligand binding assay. The cells were rinsed twice with 10 ml of ice-cold phosphate-buffered saline and mechanically detached in 1 ml of an ice-cold buffer containing 5 mM Tris⅐HCl (pH 7.4) and 2 mM EDTA. The lysate was centrifuged at 45,000 ϫ g for 10 min at 4°. The pellet containing membrane fraction was resuspended in 1 ml of buffer containing 75 mM Tris⅐HCl (pH 7.4), 12.5 mM MgCl 2 and 2 mM EDTA with Potter type homogenizer and stored at Ϫ80°until use. A competition binding assay was performed in duplicate using ϳ10 g of membrane protein, 50 pM 125 I-CYP, and 0-100 M unlabeled ligand in the presence of 100 M GTP for 60 min at 37°. The binding reaction was terminated by rapid filtration over Whatman GF/C filters and washing with an ice-cold solution containing 25 mM Tris⅐HCl (pH 7.4) and 1 mM MgCl 2 . Nonspecific binding was determined in the presence of 5 M (Ϯ)propranolol. The protein concentration was determined by the method of Lowry et al. (1951) . cAMP accumulation assay. Two days after the transfection, JEG-3 cells were incubated overnight with [ 3 H]adenine (2 Ci/ml). On day 4 the cAMP accumulation was measured in the absence of activator (basal activity) or in the presence of test compounds for 15 min at 37°with 1 mM 3-isobutyl-1-methylxanthine. The reaction was terminated by the addition of 1 ml of ice-cold stop solution containing 2.5% perchloric acid, 0.2 mM cAMP, and [
14 C]cAMP (about 10,000 cpm). After being neutralized with 4.2 M KOH, the precipitate was removed by centrifugation at 5,000 rpm for 5 min at 4°in a microcentrifuge. The supernatant was sequentially processed by Dowex and by aluminum oxide columns for isolation of [ 3 H]cAMP. Data analysis and statistics. All results are expressed as an arithmetic mean together with mean Ϯ standard error of the mean for n determinations except the K i and K d values, which are expressed as geometric means with 95% confidence limits. Equilibrium dissociation constants were determined from the saturation isotherms. Radioligand binding data were analyzed by a nonlinear regression analysis to determine IC 50 and K i values using PRISM software (GraphPAD Software, San Diego, CA). Statistical significance was assessed with the analysis of variance for multiple comparisons; a probability value of p Ͻ 0.05 was considered as a significant difference.
Results
Interaction of TA-2005 with Ser204 and Ser207 of ␤ 2 AR. To investigate whether TA-2005 interacts with the same serine residues of the ␤ 2 AR as isoproterenol, we assessed the affinities of compound I, the des-8-hydroxy derivative of TA-2005, for the S204A-and S207A-␤ 2 ARs. The K d values of 125 I-CYP for the WT-, S204A-, and S207A-␤ 2 ARs, respectively, were 56, 34, and 32 pM. TA-2005 had much higher affinity for the WT-␤ 2 AR than for isoproterenol and the affinity of TA-2005 for the S204A-␤ 2 AR was decreased 56-fold but only slightly for the S207A-␤ 2 ARs (4-fold), as compared with the WT-␤ 2 AR (Fig. 2) [see also Kikkawa et al. (1997) ]. Isoproterenol bound to the S204A-and S207A-␤ 2 ARs with 27-and 13-fold lower affinities, respectively, than to the WT-␤ 2 AR. In the present study, although the affinity of compound I for the S204A-␤ 2 AR was decreased 22-fold, the affinity for the S207A-␤ 2 AR was essentially the same as that of the WT-␤ 2 AR (Fig. 2) .
The contribution of Ser204 and Ser207 to the binding of TA-2005 was also determined by a functional assay. We used JEG-3 cells for the cAMP accumulation assay with two reasons. First, the JEG-3 cells had low basal adenylyl cyclase activity. In addition there was no significant cAMP accumulation by isoproterenol stimulation, even with high concentration (100 M) of isoproterenol. These two characteristics allowed us to detect small changes in the cAMP contents by agonist stimulation in transiently transfected cells. The EC 50 values of isoproterenol in the S204A-and S207A-␤ 2 ARs were increased by 12-and 4.3-fold, respectively (Fig. 3) , consistent with the previous report (Strader et al., 1989b) . The EC 50 values of TA-2005 and compound I were slightly increased in the S204A-␤ 2 ARs (2.0-and 7.6-fold, respectively) but not in the S207A-␤ 2 ARs. In the WT-, S204A-, and S207A-␤ 2 ARs, both compound I and TA-2005 activated the adenylyl cyclase to the same extent as isoproterenol.
Selectivity for the WT-␤ 2 AR. To determine which portion of the TA-2005 molecule is important for ␤ 2 AR selectivity, we synthesized two compounds that lack p-methoxyphenyl (compound II) or p-methoxyphenyl methylethyl groups (compound III), and examined the affinities of these compounds for the WT-␤ 1 and ␤ 2 ARs. TA-2005 showed a 53-fold higher selectivity for the ␤ 2 AR than for the ␤ 1 AR, whereas isoproterenol showed no selectivity for the ␤ 1 and ␤ 2 ARs (Fig.  4, A and B) . In contrast to TA-2005, compounds II and III completely lost their ␤AR subtype selectivity (Fig. 4, C and  D) .
Affinity for ␤ 1 /␤ 2 AR chimeras. To determine the domain(s) of the ␤ 2 -receptor that interact with the p-methoxyphenyl group on the amine portion of TA-2005, eight ␤ 1 /␤ 2 chimeric receptors were constructed and expressed in COS-7 cells (see Fig. 5 for structures). The ligand-binding properties of the resultant chimeric receptors are summarized in Tables  1 and 2 . The K d values of the radioligand 125 I-CYP in the chimeric receptors were essentially the same as those of the WT-␤ 1 and ␤ 2 ARs except in CH4 with slightly low affinity of 125 I-CYP.
When the TM2 or TM7 regions of the ␤ 2 AR were replaced with the corresponding regions of the ␤ 1 AR (CH2 and CH3), the affinities of TA-2005 were significantly decreased by 7-and 8-fold, respectively (Table 1 ). In contrast, the affinities of isoproterenol and compound III did not change significantly in CH2 and CH3. The replacement of both the TM2 and TM7 regions of the ␤ 2 AR with those of the ␤ 1 AR (CH4) markedly decreased the affinity of TA-2005 (20-fold). The affinity of isoproterenol for CH4 increased, although the extent of increase was small (1.9-fold) ( Table 1) .
The affinities of TA-2005 were not increased by the replacement of the TM1 and TM2 regions of the ␤ 1 AR with those of the ␤ 2 AR (CH5 and CH6), although these affinities would be expected to increase if these regions were involved in the ␤ 2 -selective binding (Table 2) . When the TM7 region of the ␤ 1 AR was replaced with homologous region of the ␤ 2 AR (CH7), the affinity of TA-2005 increased 3-fold. Although the affinity of TA-2005 for CH8 was essentially the same as that for the WT-␤ 2 AR, the affinities for all of the ligands were also increased in the CH8 receptor (Table 2 ). These nonspecific increases in the affinity for all of the ligands obscured the contribution of the TM2 region to the ␤ 2 selectivity.
Alanine-scanning mutants of ␤ 2 ARs. There are 10 positions in the TM7 region of the ␤ 2 AR in which the amino acid residues are different from those of the ␤ 1 AR. To identify the amino acid which is important in ␤ 2 -selective agonist binding, each of the amino acids was changed to alanine. One mutant (Y308A-␤ 2 AR) out of 10 different alanine-substituted mutants, in which Tyr308 was changed to alanine, showed a dramatically decreased affinity for TA-2005 (Table 3) . Although the Y308A-␤ 2 AR also showed the decreased affinity for isoproterenol, the extent of the decrease in affinity was smaller than that of TA-2005. Furthermore, the Y308F-␤ 2 AR mutant, in which Tyr308 in the TM7 region of the ␤ 2 AR was replaced with the corresponding amino acid residue (Phe) of the ␤ 1 AR, showed decreased affinity for TA-2005 (Y308F-␤ 2 AR: 61 nM versus WT-␤ 2 AR: 12 nM, p Ͻ 0.05), although that of isoproterenol for Y308F-␤ 2 AR was essentially the same as that of the WT-␤ 2 AR (1800 and 900 nM, respectively). The replacement of Phe359 of the ␤ 1 AR with Tyr (F359Y-␤ 1 AR), which is a complementary mutant of Y308F-␤ 2 AR, increased the affinity for TA-2005 by 2.5-fold. However, we have also observed that F359Y-␤ 1 AR decreased the affinity for 125 I-CYP by 19-fold, whereas it increased the affinity for isoproterenol by 7-fold (data not shown).
Discussion
Mutagenesis experiments have determined the binding sites of the nonselective agonists and selective antagonists for the ␤ 2 AR (Dixon et al., 1989; Frielle et al., 1988; Marullo et al., 1990) . However, the binding sites of the selective ␤ 2 AR agonists are little known. We have studied the binding sites of TA-2005, one of the most selective ␤ 2 AR agonists with a hydroxy-carbostyril structure. TA-2005 has one hydroxyl group and one amido group at positions corresponding to the p-and m-hydroxyl groups of isoproterenol, respectively (Fig.  1) .
At first, we compared the binding sites of the hydroxycarbostyril moiety of TA-2005 to those of the catechol moiety of isoproterenol. For this purpose, we synthesized compound I and constructed two site-directed mutants in which Ser204 or Ser207 in the TM5 region were changed to alanine. It was proposed that these serines should interact with the m-and p-hydroxyl groups of isoproterenol (Strader et al., 1989b) . Replacement of Ser204 or Ser207 with alanine decreased the affinities of isoproterenol and TA-2005, although the change in the affinity of TA-2005 for the S207A-␤ 2 AR was smaller than that of isoproterenol (Kikkawa et al., 1997) . In contrast with binding experiments, the functional assay for TA-2005-stimulated cAMP accumulation showed no differences in the EC 50 values of TA-2005 in the WT-␤ 2 AR and the two mutants. These data suggest that Ser204 may be an important determinant for the high affinity binding of TA-2005 but not necessarily for the activation of adenylyl cyclase. It also suggests that one of the two serines in the TM5 region of the ␤ 2 AR may be enough to activate the adenylyl cyclase by TA-2005 with high affinity. Because the affinity of compound I for the S207A-␤ 2 AR was similar to that for the WT-␤ 2 AR, and the affinity of compound I decreased in the S204A-␤ 2 AR, it seems that the 8-hydroxyl group of TA-2005 may interact with the Ser207 hydroxyl group of the ␤ 2 AR. However, it is necessary to analyze the interaction of another derivatives of TA-2005 with more mutants to determine the precise inter- The binding of ligands to the WT-and CH-␤ARs was measured by competition with 50 pM 125 I-CYP. The data were analyzed using the nonlinear least-squares regression computer program as described in Experimental Procedures. The results are shown as the means and 95% confidence limits of three to four separate experiments. There have been several reports that the TM2 region of the gonadotropin-releasing hormone receptor should be in close the proximity to the TM7 region and that both regions participate in hormone binding (Arora et al., 1996; Awara et al., 1996; Davidoson et al., 1996; Zhou et al., 1994) . To avoid the misleading conclusions that can arise from the use of loss-of-function mutants, in which chimeric receptor mutants lose their the ␤ 2 selectivity, we made a series of gain-of-function mutants, in which the chimeric receptor mutants gained ␤ 2 selectivity. The replacement of the TM7 but not the TM2 regions significantly increased the affinities of TA-2005. Although the ␤ 1 AR with both TM2 and TM7 regions of the ␤ 2 AR almost completely restored the ␤ 2 selectivity to the level of the WT-␤ 2 AR, the resultant chimeric receptor (CH8) also increased the affinity of isoproterenol. This suggests that the TM7 region of the ␤ 2 AR contributes to ␤ 2 -selective agonist binding, but the contribution of the TM2 region to this binding is not definitive. It has recently been reported that the long lipophilic side chain of salmeterol, a ␤ 2 -selective agonist, interacts with residues 149 -158 within the TM4 region of the ␤ 2 AR (Green et al., 1996) . It has also been shown that the TM4 region is a domain necessary for the persistent binding of salmeterol to the ␤ 2 AR (i.e., exosite of the ␤ 2 AR). This region, however, does not seem to contribute to ␤ 2 -selective binding of salmeterol, because the ␤ 2 AR with the TM4 region of the ␤ 1 AR lost its ability to persistently bind salmeterol but still retained the ␤ 2 selectivity. This suggests that the region that confers ␤ 2 selectivity to the ␤ 2 AR is distinct from the exosite. These results also support our assumption that the TM7 region is important for the ␤ 2 -selective agonist TA-2005 in binding to the ␤ 2 AR with high affinity.
To identify the amino acid that is important for the high affinity binding of a ␤ 2 -selective agonist, each of the amino acids in TM7 region that are different from those of the ␤ 1 AR were changed to alanine. One mutant (Y308A-␤ 2 AR) out of 10 alanine-substituted mutants significantly decreased its affinity for TA-2005. Furthermore, the affinity of TA-2005 for the Y308F-␤ 2 AR was significantly decreased, although the affinity of isoproterenol was essentially the same as that of the WT-␤ 2 AR. These results suggest that Tyr308 is a major determinant for the binding of the I-CYP and isoproterenol were also changed dramatically. This indicates that the replacement of Phe of the ␤ 1 AR with Tyr may cause an overall structural change of the ␤ 1 AR and the substituted Tyr may provide an additional binding site for the ligands. Photoaffinity labeling experiments have shown the direct interaction between the TM7 region and the aryloxy portion of the ␤AR antagonists such as pindolol, CGP-12177A, and CYP (Dohlman et al., 1988; Hockerman et al., 1996; Wong et al., 1988) . Each of the three photoaffinity labels, [
I]iodocyanopindolol-diaserine, [
125 I]iodoasidobenzylpindolol, and 125 I-asidophenyl CGP12177A was incorporated at the TM6 an TM7 regions of the purified ␤AR as well as other TM regions, depending on the photoaffinity label. These data support our assumption that N-substituent of the ligands can interact with Tyr308 in the TM7 region and contribute to subtype selective binding with high affinity.
From the results of chimeric and alanine-substituted mutants, we have concluded that Tyr308 in the TM7 region of the ␤ 2 AR is crucial for the high affinity binding of the ␤ 2 -selective agonist TA-2005. This is the first report to show that a specific residue in the TM7 region is involved in the binding of a ␤ 2 -selective agonist. It remains to be determined whether Tyr308 also plays an important role in the binding of other ␤ 2 -selective agonists such as salmeterol, formoterol and procaterol. 
